Biohaven (BHVN) said Monday that its drug candidate BHV-1300 achieved "deep lowering" of targeted immunoglobulin G, or IgG, with reduction of more than 60% in the lowest subcutaneous dose tested during the current multiple ascending dose trial.

The biopharmaceutical company said that the reduction in IgG occurred "within hours" of each weekly dose during the study and that BHV-1300 was "safe and well-tolerated" throughout the early-stage trial.

Biohaven said there were no clinically "significant" effects on albumin or liver function during the trial, and no increase in cholesterol increase was observed.

The company said it is testing higher doses of subcutaneous BHV-1300 to determine the full extend of IgG reductions.

Biohaven also said it has signed an agreement with Ypsomed, an autoinjector technology provider, to develop and manufacture the BHV-1300 in an autoinjector for self-administration.

The company said its investigational new drug application for BHV-1310, an optimized and selective IgG1, IgG2, and IgG4 degrader, has also been approved, with dosing expected in Q1 next year.

Biohaven's shares were up nearly 3% in recent Monday premarket activity.

Price: 39.50, Change: +1.03, Percent Change: +2.68